Margin.
Pace.
Position.
The whole GTM playbook is being rewritten in real time, across every commercial team at once.
This briefing tells you how the GTM playbook gets rewritten in medtech as AI compresses every commercial team. Read it before your competitors hit their first AI-native quarter.
The 10-page briefing. Worth 20 minutes.
One email. One PDF. Worth twenty minutes of your week.
We send it once. Work emails only.
Every Commercial Director at a mid-market European medtech firm has had the same Monday morning. A regional university-hospital procurement committee sent the evaluation framework Friday afternoon. Forty questions on comparative clinical effectiveness, budget-impact model, real-world evidence, and cost-per-outcome. Your tender manager has three weeks. Your head of market access is at a conference. Your top KAM knows the surgeon but has never built a budget-impact model.
You have done this job for fifteen years. The pattern used to be simple. Build reference sites with teaching hospitals. Cultivate senior surgeons as clinical champions. Train your KAMs. Run framework tenders on clinical data and pricing. The business was understandable. A strong KOL network and a credible trial dataset won most of the agreements you cared about. Something changed.
This is an industry shift and a function shift, happening at the same time. Most commercial directors are treating them as two. The ones who see them as one are going to own the next decade of medtech procurement in Europe.
Same technology. Same twelve months. Opposite outcomes. The difference is the operator, not the AI.
Your CEO is already asking you about the firm's AI position. The briefing below is what you want in your hand before that conversation.
Tenders. Discount. Retirement.
Three questions every medtech commercial director is tracking. None of them used to be the same question. They are now.
Why are we losing frameworks we should be winning?
Sector-average mid-market framework win rate on structured evaluation runs fifteen to twenty-two percent. Firms delivering submissions tied to real evidence documentation run twenty-eight to thirty-five. On forty framework tenders a year, the gap between eighteen and twenty-eight percent is eighty to two hundred million in additional pipeline.
Why are our wins increasingly on price?
Half your wins this quarter closed after a procurement-committee price concession your KAM could not refuse. The committee said the budget-impact case was thin. Your KAM had the clinical argument and nothing on cost-per-outcome. Two to five hundred basis points of operating profit per framework walks out every quarter.
What walks when our best KAMs retire?
Your top three KAMs carry a third of your revenue and every senior surgeon relationship that matters. Two are over fifty-five. Once they leave, the accounts' order frequency drops twelve to eighteen months later. There has never been a way to capture what they know. There is now.
What you get when you download
An 11-page report for Commercial Directors at mid-market European medtech firms. Designed to be read in one sitting before your next board meeting.
Your industry, your function, and why they are one problem
What is happening in medtech procurement as a sector. What is happening on your tender floor, across your KAMs, your market access team, and your marketing right now. And the intersection most commercial directors have not named yet. Plain language you can use with your CEO and COO.
Four moves across tender, marketing, KAM, and succession
How to answer framework evaluations from real evidence, not marketing narrative. How to become the preferred name in the procurement group's research before the tender drops. How to arm the KAM with committee history at the meeting. How to capture what your senior KAMs know before they retire.
Five questions for your next board meeting
Revenue defence on senior KAM exit. Framework response read as evidence or as marketing. Whether your firm appears in procurement answer-engine research. Market access bench readiness for 2027. Firm valuation at the next capital event. Ask these honestly.
Calibrated for each seat at the table.